Sanofi Genzyme announced the start of their phase 4 study (B-CLEAR1, LPS15918), an open-label, multicenter, multinational, randomized, controlled, prospective clinical trial

Sanofi Genzyme announced the start of their phase 4 study (B-CLEAR1, LPS15918), an open-label, multicenter, multinational, randomized, controlled, prospective clinical trial. The primary objective is to assess the reduction of plasma lyso-GL-3 in each group 12 months after randomization. The secondary objectives are to assess the reduction of kidney podocyte GL-3 and endothelial skin cells … Continue reading “Sanofi Genzyme announced the start of their phase 4 study (B-CLEAR1, LPS15918), an open-label, multicenter, multinational, randomized, controlled, prospective clinical trial”

Read More

FIN Newsletter December 2019

Dear All The last Newsletter of 2019! In this edition we continue to share a lot of information and announce a vacancy for the FIN Board. We would also like to draw your attention to our next FIN Expert meeting, next year in Amsterdam.  We look forward to seeing you all at the meeting. FIN … Continue reading “FIN Newsletter December 2019”

Read More

Subscribe to Our Newsletter